title: Optimising therapy for EGFR-addicted NSCLC: just the start.
authors.affiliation: Division of Oncology, Department of Medicine, and Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA. rgovinda@dom.wustl.edu
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
authors.forename: Janakiraman
authors.initials: J
authors.lastname: Subramanian
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors